March 14th 2024
In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Addressing Unmet Needs and Treatment Gaps in the Clinical Management of Neovascular Age-Related Macular Degeneration: Practical Strategies for Pharmacists in Specialty and Man...
1.5 Credits / Ophthalmology/Optometry
View More
Management of Neuromyelitis Optica Spectrum Disorder: Expert Insights and Updates for Pharmacists, featuring a Patient Perspective
1.5 Credits / Ophthalmology/Optometry
View More
The Promising Role of Novel Targeted Therapies in Addressing Clinical and Economic Burdens in Diabetic Macular Edema
1.5 Credits / Ophthalmology/Optometry
View More
Improving Outcomes and Quality of Care in Age-Related Macular Degeneration and Diabetic Macular Edema: Patient-Centered Strategies in Managed Care
3.0 Credits / Ophthalmology/Optometry
View More
Maximizing Patient Outcomes in Ophthalmologic Diseases: How Managed Care Professionals Play a Key Role in Facilitating Uptake of Biosimilars
1.0 Credit / Ophthalmology/Optometry
View More
Opinion: A Modified 351(a) Licensing Pathway for Biosimilars
August 21st 2021Use of the 351(k) biosimilar approval pathway entails legal challenges, high costs, and potentially higher clinical evidence standards. Sarfaraz K. Niazi, PhD, suggests that using the 351(a) pathway for standalone drugs and copy products may be faster and better. This is part 3 of a series.
An Interview With the AAO About Its Bevacizumab Concerns
August 10th 2021"[Payers] are incorrectly assuming that biosimilars of bevacizumab are going to behave the same as Avastin in the eye, and they’re making that assumption with absolutely no data," contends George Williams, MD, clinical spokesperson and past president of the American Academy of Ophthalmology (AAO).
Formycon and Bioeq Update on Ranibizumab BLA, and Coherus Reports Earnings
August 6th 2021After a delay caused by a manufacturing shift, Formycon and Bioeq are back on track with their ranibizumab biologics license application (BLA), and their partner Coherus BioSciences is aligned for US commercialization.